Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Sponsor: The First People's Hospital of Changzhou
Summary
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
Official title: The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2015-06
Completion Date
2033-06
Last Updated
2016-02-19
Healthy Volunteers
No
Conditions
Interventions
Cytokine-Induced Killer Cells
Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
Apatinib
Advanced gastric cancer patients take Apatinib 850mg qd by mouth.